fbpx
  • Panels
    • ePlex Panels
      • Respiratory
      • Blood Culture
    • XT-8 Panels
  • Systems
    • ePlex System
      • Software Solutions
      • Patient Safety
    • XT-8 System
  • Company
    • The GenMark Story
    • Careers
      • Opportunities
    • Newsroom
  • Education
    • Disease State
      • Sepsis
      • Respiratory Infections
      • Hepatitis C
      • GI Infections
    • Technology
    • Resources
  • Support
    • Contact Us
    • FAQs
    • Safety Data Sheets (SDS)
    • Your Long-Term Partner
  • Customer Resource Center
Select your region:
  • International
    • United States
SELECT YOUR REGION:
  • International
    • United States
| CONTACT US | CUSTOMER RESOURCE CENTER
GenMark
  • Panels
    • ePlex Panels
      • Respiratory Pathogen Panels
      • Blood Culture
  • Systems
    • ePlex System
      • Software Solutions
      • Patient Safety
  • Company
    • The GenMark Story
    • Careers
    • Newsroom
  • Education
    • Disease State
      • Sepsis
      • Respiratory Infections
      • GI Infections
    • Technology
    • Resources
  • Support
    • Contact Us
    • FAQs
    • Safety Data Sheets (SDS)
    • Long-Term Partner
  • Customer Resource Center

Detection of variant SARS-CoV-2 strains on the ePlex® RP2 Panel*

December 3, 2021

As genetic surveillance of SARS-CoV-2 strains circulating globally continues to identify new variants and mutations that can potentially impact detection by nucleic acid-based testing methods, GenMark conducts routine sequence analysis of available SARS-CoV-2 strains in the GISAID database to monitor for mutations that may impact performance of the ePlex Respiratory Pathogen 2 Panel (RP2 Panel) SARS-CoV-2 assays.

 

The ePlex RP2 Panel targets 2 unique regions of the N (nucleoprotein) gene. Mutations in other regions of the genome, such as the spike protein or envelope protein, have no impact on the performance of the SARS-CoV-2 assays on the ePlex RP2 Panel. The bioinformatic assessment includes expected performance of both the N1 and N2 SARS-CoV-2 assays for any mutation located within the gene regions targeted by these assays.

 

The table below summarizes known SARS-CoV-2 variant strains and the impact, if any, on the ePlex RP2 Panel based on bioinformatic analysis.

  • This list will be updated as new information becomes available.
  • This list is not intended to be a comprehensive list of all variants or mutations identified; it includes the most prevalent variants in circulation believed to be clinically significant. Strains no longer circulating and strains no longer being monitored have been removed from the table.
  • For the most up to date information on variants, please refer to your regional health authorities.

 

Click here to learn more about Omicron variant detection on the ePlex RP2 Panel.

WHO Label

Pango Lineage

N Gene Mutations Associated with Variant

Impact to ePlex RP2 Panel

Alpha

B.1.1.7

D3LD3L
R203K

G204R
S235F

Detected

Beta

B.1.351

T205I

Detected

Gamma

P.1

P80R
R203K

G204R

Detected

Delta

B.1.617.2
AY.4.2
AY.43
AY.33
AY.34

D63G
R203M

G215C
D377Y

Detected

Eta

B.1.525

S2Y
Del3

A12G
T205I

Detected

Iota

B.1526

P199L

M234I

Detected

Kappa

B.1.617.1

R203M

D377Y

Detected

Lambda

C.37

P13L
R203K

G204R
G214C

Detected

Mu

B.1.621
B.1.621.1

T205I

Detected

Omicron

B.1.1.529

BA.1
BA.2
BA.3

P13L
Del31-33

R203K

G204R
S413R (BA.2
and BA.3 only)

Detected

AZ.5 (formerly tracked as B.1.1.318)

R203K
G204R

A208G
Del209

Detected

IHU

B.1.640.2
B.1.640.1 (previously known as B.1.640)

D22Y

T205I

E378Q

Detected

C.1.2

P13L

R203K

G204R

Q384H

Detected

*The ePlex RP2 Panel is for use under Emergency Use Authorization (EUA) only. This test has not been FDA cleared or approved. This test has been authorized by FDA under an EUA for use by authorized laboratories. This test has been authorized only for the simultaneous qualitative detection and differentiation of nucleic acid from SARS-CoV-2 and multiple respiratory viral and bacterial organisms; and this test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

 

GenMark Diagnostics, Inc.
5964 La Place Court
Carlsbad, CA 92008

 

© Copyright 2022 GenMark Diagnostics, Inc.
All rights reserved.

 

info@genmarkdx.com
P: +1 760-448-4300
F: +1 760-448-4301

 

Legal | Privacy Policy

 

 

This website uses cookies to improve your experience. Read More. You can opt-out if you wish. Change settingsACCEPT REJECT
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT
Popup Button